Completed
PHASE4
INTERVENTIONAL
NCT05786521
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.
Interventions
Name:
Semaglutide Injectable Product
Type:
DRUG
Description:
Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks.
Name:
Lifestyle Counseling
Type:
BEHAVIORAL
Description:
Lifestyle Counseling will be provided throughout study intervention
Primary Outcomes
Measure:
Lean Body Mass Change
TimeFrame:
Baseline to 20 weeks
Description:
Determine if there is any change in lean body mass
Trial Information
NCT ID
NCT05786521
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
The University of Texas Health Science Center at San Antonio
Last Updated
December 15, 2025